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Purpose : To investigate the concentrations of steroid hormones (estradiol, progesterone),
pregnancy–associated protein-A, IGF-binding protein-4 and leptin in the follicular fluid of
infertile patients with and without endometriosis.
Methods : Follicular fluid of IVF patients with and without endometriosis was aspirated, cen-
trifuged and stored to analyze the above mentioned hormones and to compare their concen-
trations between women with and without endometriosis.
Results : Follicular fluid estradiol levels were significantly higher in controls than in affected
women. The concentrations of the other markers did not differ between the two groups.
Conclusions : Since not only the follicular fluid concentration of estradiol, but also the oocyte
quality is decreased in women with endometriosis, we suggest that estradiol can be considered
as a marker not only of oocyte maturity but also of oocyte quality.
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INTRODUCTION
Endometriosis, which is characterized by the pres-
ence of endometrial tissue outside the uterus, is
an enigmatic, chronic, progressive and inflammatory
disease, associated with local and systemic abnor-
malities in the immune response and leading to in-
fertility and pain. Leptin, the hormone encoded by
the obesity (ob) gene, was firstly thought to have
only anti-obesity properties, but many studies (1,2)
have shown that leptin also had proinflammatory, im-
munoregulatory and angiogenic effects, all of which
play a role in the pathogenesis of endometriosis.
Leptin influences reproduction and fertility (3) and
may be involved in the pathogenesis of endometrio-
sis (4). Pregnancy–associated protein-A (PAPP-A)
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is a high molecular weight, highly glycosylated 2 ×
2-heterotetrameric polypeptide linked to the pro-
form of the eosinophilic major basic protein (5). Its
biological role has been unclear, but it has been
recently found (6) to have a protease activity to-
wards insulin-like growth factor-binding protein 4
(IGF-bp4) and has been suggested to play a role in
follicle selection and granulosa luteinization (7). Re-
cently, increased concentrations of PAPP-A in the
peritoneal fluid of women with endometriosis were
reported (8). IGFs are stimulating steroidogenesis
and IGF-bps are effective antigonadotropins; they
both play a key role in ovarian follicular develop-
ment (9). Insulin-like growth factor binding protein-
4 (IGF-bp4) is an inhibitor of IGF action and with
that a potent inhibitor of FSH stimulated granu-
losa steroidogenesis (10). By regulating FSH action,
both IGF and IGF-bps play a key role in ovar-
ian follicular development (9). By cleaving IGF-bp4,
PAPP-A is providing higher IGF-II activity in the
follicles, which is important for follicle growth and
survival.
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The outcome of in vitro fertilization (IVF) treat-
ment is poorer for patients with endometriosis
than for patients with other causes of infertility
(11,12,13,14,15), but whether the reduced pregnancy
rate in endometriosis is due to embryo quality, the
endometrial environment, or both is controversial.
Consequently, it is most critical to elucidate the
pathophysiological mechanism of endometriosis and
to find out why this disease has a negative influence
on fertility. It was shown that oocytes of women with
endometriosis are of inferior quality and have lower
implantation rates in IVF than oocytes from women
with other origins of infertility (12). There is increas-
ing evidence that not only the gonadotropins, but
also cytokines, growth factors as well as the locally
produced steroid hormones themselves are modu-
lating the folliculogenesis. It is to be expected that
the follicular fluid in patients with endometriosis is
different from the one from other women (fertile
or infertile) and this may be responsible for the in-
ferior quality and implantation potential of these
oocytes.
Controlled ovarian stimulation in assisted repro-
duction gives us the unique opportunity to study the
dynamic changes occurring in follicular fluid (FF)
composition under the influence of gonadotropins.
FF contains a variety of growth factors, cytokines,
prostaglandins and steroid hormones secreted by the
cells of the ovarian follicle. The objective of the
present study was to investigate the mechanisms as-
sociated with infertility in patients with endometrio-
sis through the analysis of the steroid hormones
estradiol (E2) and progesterone (Prog), the hormone
leptin and the protein markers pregnancy-associated
plasma protein-A (PAPP-A) and insulin-like growth
factor-binding protein-4 (IGF-bp4) in the follicu-
lar fluid of infertile patients with and without the
disease.
MATERIALS ANDMETHODS
Patient Characteristics
The present study contained 326 analyses of follic-
ular fluid of patients undergoing assisted reproduc-
tion between September 1999 and December 2003.
The fluids were collected at oocyte pick-up from
patients undergoing IVF and embryo transfer. For
being included in the study, the patient in reproduc-
tive age (maximum 42 years) had to provide written
consent for the treatment by intracytoplasmic sperm
injection (ICSI). Only ICSI-cycles were included to
have a more homogenous population. Hormonal
values, gynecological ultrasound results and cervical
smears had to be normal, and no infectious diseases
(Rubella, HIV, Hepatitis B, Hepatitis C, Syphilis)
were allowed to be present. Criteria for exclusion
from an IVF/ICSI-treatment were acute or chronic
infectious diseases, severe psychiatric problems, or
being a carrier of severe genetic diseases. Diagnosis
of endometriosis was based on histological analyses
of laparoscopically taken biopsies. In our study group
there were 47 patients with diagnosed endometriosis,
of which 33 were mild (rAFS stages I or II) and
14 severe (rAFS stages III or IV) cases and 279
controls.
Protocol for Controlled
Ovarian Stimulation
Ovarian stimulation and oocyte retrieval were
usually performed using a “long” protocol, with
downregulation starting in the luteal phase of the
previous cycle with the agonist Triptorelin, 0.1 mg
per day s.c. (Decapeptyl, Ferring pharmaceuticals,
Wallisellen, Switzerland) until complete pituitary
desensitization was documented. Stimulation was
initiated, once sonographic evidence indicated no
ovarian follicular activity and serum levels of human
chorionic gonadotropin (hCG) and estradiol were
below 2 mIU/mL and 130 pmol/L, respectively,
in most cases with recombinant FSH (Gonal-F,
Serono Pharma, Geneva, Switzerland or Puregon,
Organon Pharmaceuticals, Pfa¨ffikon, Switzerland)
or with menopausal gonadotropin (hMG, Pergonal,
Serono or Humegon, Organon). Follicular matura-
tion was assessed by ultrasound and serum estradiol
measurements. hCG (5,000–10,000 IU, Profasi,
Serono or Pregnyl, Organon) was administered
when at least three follicles exceeded 17 mm in
diameter and the estradiol concentration per mature
follicle exceeded 1000 pmol/L.
For low responders the short protocol was used.
Downregulation was performed on the first day
of the cycle with Triptorelin, 0.05 mg per day.
Gonadotrophin stimulation (see above) was initi-
ated on the second day of the cycle after sono-
graphic evidence indicated no ovarian follicular
activity and serum hCG was below 2 mIU/mL.
hCG (10,000 IU) was given as above to induce
ovulation.
Short and long protocols were equally distributed
in both groups, the short protocol accounting for
less than 5% in both groups. Similar distribution was
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also the case with the different gonadotrophins used
(rFSH or HMG).
In the case of hyper-responders with E2 lev-
els greater than 10,000 pmol/L and consequently
an increased risk of developing a hyperstimulation
syndrome, only 5,000 IU hCG were administered.
In the endometriosis group, there were nine hy-
perresponders (of totally 47 patients), in the con-
trol group there were 65 (of 279), p = 0.7066,
(n.s. by Fishers Exact test). Concerning the low re-
sponse, there were nine (in a total of 47 patients)
in the endometriosis group, and 38 (of 279) in the
control group, p = 0.1544 (n.s. by Fishers Exact
test).
Thirty-five to 36 h after the administration of hCG,
the fluid containing the oocytes was retrieved from
all follicles by needle aspiration, with transvaginal
ultrasound guidance and under routine intravenous
sedation.
Assessment for Oocyte Maturity,
ICSI and Embryo Culture
Hyaluronidase denuded oocytes were assessed for
maturity. Only metaphase-II oocytes, identified by
the presence of the first polar body, were chosen for
fertilization. ICSI was performed 3–6 h after oocyte
recovery by using previously described (16) tech-
niques and instrumentation.
Embryo Grading, Selection
and Transfer
Fertilization was assessed 17 h after IVF or ICSI.
Only normally fertilized oocytes (two pronuclei (PN)
and two polar bodies) were considered for em-
bryo transfer, and cryopreservation was performed
at this stage when more than two normally fertilized
oocytes were available. The cells with the highest PN
score and with the best morphological grade were
selected for transfer and cultured for another 20–
30 h at 37◦C in fresh CO2 equilibrated IVF medium
(Vitrolife, Go¨teborg, Sweden). The remaining, nor-
mally fertilized oocytes were cryopreserved in the
PN stage according to the Swiss law. Embryo de-
velopment was evaluated 2 to 3 days after ICSI or
insemination by determining the number of blas-
tomeres and the relative proportion of anucleate
cell fragments. Embryos with less than 10% frag-
ments, with 10–20% fragments, and with 20–30%
fragments were referred to as grade 1, 2 and 3,
respectively.
Measurement of Hormones and
Cytokines in Follicular Fluid
FF samples from individual follicles were pooled
and centrifuged for 10 min at 500 × g and the super-
natants were stored at −30◦C until analyzed further.
Fractions of FF with massive blood contamination
were excluded.
Steroid Hormones. Estradiol-17β and proges-
terone were determined by competitive radio-
immunoassay using coated tube methodology. The
kits (”Coat-a-Count”) were manufactured by DPC,
Los Angeles, USA and obtained from Buhlmann
Laboratories, Basle, Switzerland. Samples were
diluted 1:250 (estradiol) and 1:500 (progesterone) in
the diluent provided. The 3-h incubation protocol
was used. Intra- and interassay coefficients of
variance at halfmaximal binding were 4.3 and 6.8%
for estradiol, and 3.9 and 5.5% for progesterone,
respectively.
Pregnancy-Associated Plasma Protein A (PAPP-
A). This protein was determined with a double
antibody microplate enzyme immunometric assay
(ELISA), marketed by Buhlmann Laboratories,
Switzerland and involving a capture antibody puri-
fied by negative affinity chromatography (17). A di-
lution of 1:11 was used; the method and assay param-
eters are described elsewhere (17).
IGF-Binding Protein 4 (IGF-bp4). This analyte
was quantified similarly by microplate ELISA.
The monoclonal capture antibody, the biotinylated
polyclonal (goat) detection antibody and the
recombinant human IGF-bp4 (Asp22-Glu258)
standard were obtained from R&D systems. Briefly,
microplate wells (Maxisorp, Nunc, Denmark)
were coated with 100 µL of the capture antibody
(2 µg/mL) in phosphate buffered saline (PBS)
overnight at 4◦C, and excess sites were then blocked,
without previous washing, with bovine serum albu-
min (BSA, 0.5 mg/mL, Fluka, Buchs, Switzerland)
in PBS for 1 h at 30◦C. Then the plates were washed
in two aspiration cycles using PBS with Tween-20
(PBST, 0.1% v/v; Sigma, Fluka, Buchs, Switzerland)
and follicular fluid samples (1:50) and standard (16
to 0.25 ng/mL in serial 1:2 steps) were diluted in
PBS containing 5% (v/v) Tween-20 without carrier
protein, and incubated for 2 h at 30◦C under slow
shaking (300 rpm) in a Thermostar dry incuba-
tor/shaker. After three washing steps with PBST, the
detection antibody (400 ng/mL in PBS containing 5%
(v/v) Tween-20 and 2% (v/v) heat-inactivated normal
goat serum obtained from the Scottish Antibody
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Production Unit, Carluke, Scotland) was added and
the plates incubated as above. After three more
washing cycles, streptavidin-conjugated horseradish
peroxidase compound (Southern Biotech, USA;
Bioreba, Reinach, Switzerland), diluted 1:4000
in Blotto (Pierce, USA; Socochim, Lausanne,
Switzerland), was added and the plates incubated for
30 min under the same conditions. After extensive
washing (five aspirations) the colour was developed
using the same protocol as for leptin (18).
Leptin. This hormone was quantified with an
ELISA developed in our laboratory using mono-
clonal “matched-pair” (capture and detection) an-
tibodies obtained from R&D Systems, Abingdon,
England. The recently described (18) method was
followed with the exception that the samples (1:50 di-
lution) and standards (1000–15.6 pg/mL in serial
1:2 steps) were incubated in RD5P medium (R&D
Systems, England). Subsequent incubations were in
Blotto (Pierce, USA). The chromogenic detection
method and the coefficients of variance have been
reported (18).
Statistics
Except for the normally distributed clinical vari-
ables (Table I) non-parametric, two-tailed Mann–
Whitney U test and 2 × 2 contingency tables were
used as indicated. A p value of 0.05 or less was ac-
cepted as significant.
RESULTS
Clinical Data and IVF Treatment Outcome
In our total sample of 326 women undergoing IVF
treatment and fulfilling the inclusion criteria, 47 were
diagnosed with endometriosis. Table I, top section,
shows the pretreatment and clinical data. There were
no statistically significant differences, including ovar-
ian reserve, between the groups. The results for the
outcome parameters of the IVF treatment are given
in the second part of Table I.
Steroid Hormones, PAPP-A, IGFbp-4 and
Leptin Concentrations in Follicular Fluids
Follicular fluid concentrations for estradiol were
significantly reduced in endometriosis patients in
comparison to the non-endometriosis controls. On
the other hand, no significantly different follicular
fluid levels between the two groups were observed
Table I. Pre-IVF Treatment and Clinical Parameters and IVF
Outcome Data for the Study Patients of the Two Groups,
Controls and Cases of Endometriosis
Control group Endometriosis p
Clinical parameter (n = 279) group (n = 47) value
Maternal age (years) 33.2 ± 4.1 33.0 ± 3.7 0.7254a
(Mean ± SD)
Body mass index (kg/m2) 23.9 ± 3.8 22.8 ± 3.7 0.0575a
(Mean ± SD)
Basal FSH (mIU/mL) 7.7 (2.4–24.8) 7.6 (2.8–19.8) 0.7044b
(Median, Range)
Oocytes retrieved (N) 8.6 ± 4.5 7.8 ± 4.4 0.3767a
Embryos transferred/ET 1.72 ± 0.67 1.51 ± 0.69 0.0498a
Cancelled transfers (N)c 24 of 279 5 of 47 0.5869d
No Pregnancy 202 of 279 37 of 47 0.4760d
(all cycles)
Biochemical 15 of 279 3 of 47 0.7276d
pregnancies
Miscarriages 7 of 279 1 of 47 1.00
Ongoing 55 of 279 6 of 47 0.3157d
pregnancies
Pregnancy rate 30.2 23.8
per transfer (%)
aBy Student’s t-test.
bBy Mann–Whitney U-test.
cFertilization and cleavage failures or threatening hyperstimula-
tion syndrome.
dBy Fisher’s Exact test (2 × 2 contingency table).
for progesterone, leptin, PAPP-A and IGF-bp4. The
results are presented in Table II.
Leptin concentrations in the follicular fluid
correlated strongly and significantly (p < 0.0001)
with the body mass index, irrespective of the
absence or presence of endometriosis but in an
even more pronounced way in the latter group.
The results are presented in Fig. 1. PAPP-A levels
were strongly (p < 0.0001) and positively correlated
to progesterone in both groups, and negatively to
estradiol in the controls (p = 0.0201). Moreover,
PAPP-A was positively correlated to IGF-bp4 in
the control group (p = 0.0293, Fig. 2A), with leptin
presenting the same pattern to an even stronger
extent (p = 0.0005, Fig. 2B). No associations,
however, were found between steroid hormones and
leptin.
DISCUSSION
We have found a significantly decreased follicular
fluid concentration of estradiol in endometriosis
patients compared to controls, but no difference in
progesterone levels which is in contrast to Pellicer
et al. (19) who found that these levels were increasing
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Table II. Ovarian Steroid Hormones, Leptin, PAPP-A and IGF-Binding
Protein-4 (Median, Range) in the Pooled Follicular Fluid of Women with
and Without Endometriosis
Hormone or Control group Endometriosis
growth factor (n = 279) group (n = 47) p value
Estradiol (nmol/L) 823 (79–5832) 641 (134–3545) 0.0279
Progesterone (µmol/L) 28.92 (1.59–119.2) 28.31 (7.29–45.09) 0.9328
Leptin (ng/mL) 14.15 (1.23–66.95) 11.38 (2.01–56.73) 0.1655
PAPP-A (mIU/L) 1.37 (0.02–2.89) 1.31 (0.66–2.58) 0.6143
IGF-bp4 (ng/mL) 123 (64–184) 122 (84–188) 0.7722
with the severity of the disease. This discrepancy
is difficult to explain, but it may be related to
lower numbers in the mentioned study (particularly
the controls) and to different distribution of the
patients between the various types of infertility
(tubal vs. male) in the control group. Other studies
of natural and stimulated cycles did not indicate any
differences of steroid levels in the serum and FF in
endometriosis patients compared with controls. We
have, however, also observed slightly lower estradiol
levels in the serum (on the day of oocyte retrieval)
in our endometriosis patients (median, 2.88 nmol/L)
than in the controls (median, 4.34 nmol/L), and
serum and follicular fluid estradiol levels correlated
Fig. 1. Follicular fluid leptin concentrations as a function of the
body mass index. The individual values and the regression lines
are represented as dots and a solid line for the controls and
as open circles and a dashed line for the cases of endometrio-
sis. Regression parameters for slope, r and p are 2.136, 0.4192,
and < 0.0001 for controls and 3.002, 0.5334, and <0.0001 for en-
dometriosis, respectively.
strongly with each other in both groups (p < 0.01
by Spearman Rank correlation analysis). In our IVF
centre, more than 90% of the couples were referred
for reasons of male infertility; our control population
could thus be closer to the normal, fertile one which
is reacting better to the gonadotrophin stimulation,
resulting in higher FF estradiol levels. Our signif-
icantly increased estradiol levels together with the
better pregnancy rates of the control group in our
study correspond to the finding that fertilized oocytes
came from follicles whose FF contained higher estra-
diol levels, and the best cleavage rate is obtained
from follicles containing more estradiol (20).
Data on leptin in the context of fertility are con-
troversial. An earlier report suggested low serum lev-
els to be related to infertility (3), a finding which has
not been confirmed. One study reported an increased
leptin concentration in peritoneal fluid in women
with peritoneal endometriosis (21). Information on
leptin levels in the follicular fluid of endometriosis
patients is scarce, but we are confirming the paral-
lelism between serum and follicular fluid via correla-
tion of the latter with the BMI. The effect of leptin
on ovarian steroidogenesis is altogether controver-
sial, and only limited data exist regarding the ovarian
function and leptin. A positive relationship between
the increase in estrogen and leptin was reported (22),
and another study suggested a direct stimulation by
leptin of estradiol, but not of progesterone produc-
tion in cultured granulosa cells (23). Another study
(24), however, indicated no effect of leptin on estra-
diol or progesterone production in granulosa cell
culture and Ghizzoni et al. (25) even suggested an
inhibition of steroid biosynthesis by leptin in such
cultures. In this study we did not observe any as-
sociations amongst follicular fluid leptin and steroid
hormone levels.
The results of studies trying to establish a cor-
relation between leptin levels and the outcome of
IVF treatment are controversial, too. Better preg-
nancy rates in the case of lower serum leptin levels at
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Fig. 2. Follicular fluid PAPP-A (A, left panel) and leptin (B, right panel) concentrations as a function of
the concentration of IGF-bp4. The individual values and the regression lines are represented as dots and
a solid line for the controls and as open circles for the cases of endometriosis. Regression parameters
for slope, r and p values in the control group are 1.72 × 10−3, 0.125, and 0.0365 for PAPP-A, and 0.067,
0.206, and 0.0005 for leptin, respectively. No significant association was observed for these parameters
in the endometriosis group.
baseline or at the day of the administration of hCG
were reported (26), and the same was suggested to be
the case for follicular fluid in a conference abstract at
a recent Annual Meeting of ESHRE (2003). These
observations would be in theoretical agreement with
the reported decreased pregnancy rates and con-
comitantly elevated levels of leptin in endometriosis
patients (11). Moreover, the reduced estradiol levels
in the follicular fluid observed here may strengthen
the hypothesis of the inhibitory role of leptin at the
level of the granulosa cell, although the causal rela-
tionship of this interaction can only be elucidated by
in vitro studies at the cellular level. Another report
(27), however, did not find any association of FF lep-
tin levels and outcome, which is in agreement with
our own observation from this study (p = 0.5386).
Data on the body mass index (BMI) in women
with endometriosis are scarce and controversial. One
study (28) reported endometriosis patients to be un-
derweight more frequently, which is in contrast to
McCann et al. (29) who did not observe a significant
difference of body fat distribution or BMI between
women with endometriosis and controls. In the pop-
ulation of our own study presented here, the BMI in
the endometriosis group was indeed lower than in the
controls (Table I), but statistical significance was not
reached.
The knowledge on the possible function and clin-
ical usefulness of PAPP-A outside pregnancy is still
very thin. Increased PAPP-A levels have been found
in the peritoneal fluid of women with endometrio-
sis in one study (8), but results on PAPP-A in the
FF of such patients are not available. Concerning
the outcome, a positive relationship between ele-
vated follicular fluid PAPP-A levels and the chance
of achieving a pregnancy in that cycle is supported
by an observation (30) that PAPP-A gene expres-
sion in human ovaries is restricted to healthy follicles.
We have observed a significant, positive correlation
between PAPP-A and IGF-bp4 levels in the FF of
our control group (p = 0.0365) which is difficult to
explain: The reported role of PAPP-A as a specific
protease to IGF-bp4 would rather suggest a negative
association. The situation in the ovary, however, has
not been specifically explored and may differ from
the one in fibroblasts, trophoblast, and endometrium.
An autoregulatory “short” loop may thus be func-
tioning for PAPP-A at the level of the follicle. On the
other hand, we have observed a pronounced positive
correlation between follicular fluid levels of PAPP-A
and progesterone, while the association with estra-
diol is negative. The further investigation of this ex-
tremely complicated pattern for the role of ovarian
PAPP-A will be very challenging; one of the major
problems is certainly the difficulty to select a proper
control population with absolutely fertile women
undergoing ICSI treatment only because of pure
male factor. It will thus always remain difficult to
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compare the observations from different projects and
to reconcile results which seem inconsistent or even
contradictory.
A recent report has demonstrated that pre-IVF
surgery did not improve the subsequent embryo and
outcome parameters (31). The gained knowledge on
the basics of folliculogenesis, however, will improve
long-term treatment of infertility.
CONCLUSIONS
In conclusion, while the follicular fluid levels of
progesterone, PAPP-A, IGF-bp4 and leptin showed
no significant differences between IVF patients with
and without endometriosis, the results of our study
indicate that FF estradiol concentrations contrast sig-
nificantly between the two groups. As the oocyte
quality is also decreased in women with endometrio-
sis, estradiol can be considered as a marker not only
of oocyte maturity but also of oocyte quality, but this
without the reduced estradiol necessarily being the
consequence of poor quality, i.e. the causal relation-
ship cannot be determined in this type of study. In
vitro investigations would be required to address this
point, but they are illegal in Switzerland. Moreover,
the assessment of the role of the other markers and
their clinical potential in fertility related investiga-
tions requires a larger number of endometriosis cases
as well as in vitro studies.
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